Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
JU
Jupiter Neurosciences, Inc. Common Stock
JUNS
Mkt Cap
$3.8M
Volume
13.79K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
JU
JUNS
JU
Jupiter Neurosciences, Inc. Common Stock
JUNS
News
·
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Mkt Cap
$3.8M
Volume
13.79K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on CNS disorders and neuroinflammation, announced a registered direct offering of 7,142,858 shares of common stock for approximately $2.0 million gross proceeds. The offering is expected to close on May 21, 2026, with D. Boral Capital LLC serving as the exclusive placement agent.
GlobeNewswire Inc. · May 20, 2026
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
Jupiter Neurosciences (NASDAQ: JUNS) announced a webinar on January 6, 2026, where CEO Chister Rosén will discuss the company's JOTROL™ resveratrol platform, upcoming Phase 2a Parkinson's disease trial, and commercialization of its Nugevia™ consumer product line. The company is pursuing a dual-path strategy combining pharmaceutical development with consumer longevity products.
GlobeNewswire Inc. · Dec 23, 2025
Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science
Jupiter Neurosciences announced a significant advancement in resveratrol technology with JOTROL™, achieving nine-fold increased bioavailability and reduced gastrointestinal side effects, with potential applications in neurodegenerative disease treatment and consumer supplements.
GlobeNewswire Inc. · Jul 23, 2025
Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
Jupiter Neurosciences announced the launch of Nugevia, a new consumer longevity supplement line powered by its patented JOTROL delivery platform. The company has partnered with professional golfer Annika Sörenstam as the brand ambassador for Nugevia.
GlobeNewswire Inc. · Jun 23, 2025
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
Jupiter Neurosciences, a clinical-stage pharmaceutical company, has announced the closing of its $11 million initial public offering. The company plans to use the proceeds to fund a Phase II clinical trial for its product candidate JOTROL™ in Parkinson's Disease, as well as for other research and development activities.
GlobeNewswire Inc. · Dec 4, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
JU
JUNS
Jupiter Neurosciences, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
JUNS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any JUNS yet.
Related Tickers
Earnings